Treatment Information

Back

Lung Cancer treatment details. Chemotherapy, Biologic therapy.

Eli Lilly and Company, Indianapolis, IN , United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Indianapolis, IN
Treatments:Chemotherapy, Biologic therapyHospital:Eli Lilly and Company
Drugs:Journal:Link
Date:May 2006

Description:

Patients: This Phase II trial involved a total of 53 patients with advanced non-small-cell lung cancer. There were 35 men and 18 women and the median age was 67. Twenty-seven patients had adenocarcinoma, 13 had squamous cell, 2 had large cell, and 11 were consider “unclassified/other.” Forty-five patients had stage IV and 8 patients had stage IIIB. None of the patients had received prior chemotherapy.

Treatment: The treatment consisted of chemotherapy (gemcitabine and pemetrexed). In addition, all patients received folic acid, vitamin B12, and steroid prophylaxis.

Toxicity: Grade 4 toxicities included hematologic, dyspnea, pyrexia, and pleural effusion.

Results: The median overall survival was 10.3 months.

Support: The study was supported by Eli Lilly and Company.

Correspondence: Joseph Treat, MD




Back